Clinical Trial Update: Isoprostane/FMD Study The Effect of Protein Kinase C (PKC) β Specific Inhibitor LY333531 on Oxidant Stress in Patients With Type 2 Diabetes Mellitus [Phase 1]

View source ↗

Summary

Phase 1 trial assessing the PKCβ inhibitor ruboxistaurin (LY333531) on oxidative stress in patients with Type 2 diabetes mellitus; the study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Ruboxistaurin (ruboxistaurin)

Snippet

Sponsor: Chromaderm, Inc. | Conditions: Diabetes Mellitus | Phase 1 | Status: COMPLETED